| Bioactivity | Intralipid 20% is a safe fat emulsion that can be used as a nutritional supplement. Intralipid 20% effectively inhibits the opening of the mitochondrial permeability transition pore, effectively protecting the heart from ischaemia-reperfusion injury and has some potential to modulate the innate immune response[1][2]. |
| Invitro | Intralipid 20% (0-0.2 mg/mL) 可特异性保护免疫细胞免受紫杉醇的侵害，但对肿瘤细胞没有影响[1]。Intralipid 20% (0-0.2 mg/mL，3天) 促进 M0、M1 和 M2 巨噬细胞极化为 M1 样表型[1]。 |
| In Vivo | 在 Balb/c 小鼠的乳腺癌肿瘤切片中观察到，Intralipid 10% 不会影响吞噬作用，并可能促进巨噬细胞极化为 M1 表型[1]。Intralipid 10% 预处理促进紫杉醇在肿瘤组织中的积累，并诱导肿瘤细胞更高水平的凋亡。 增加紫杉醇在小鼠 RES 器官中的分布并增强对肿瘤生长的抑制作用[1]。Intralipid (5 mL/kg) 比环孢菌素-A 更有效地保护 SD 大鼠心脏免受 I/R 损伤，使心肌梗死面积减少约 40%[2]。 |
| Name | Intralipid 20% |
| CAS | 68890-65-3 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Jingyuan Li, et al. Intralipid, a clinically safe compound, protects the heart against ischemia-reperfusion injury more efficiently than cyclosporine-A. Anesthesiology. 2012 Oct;117(4):836-46. [2]. Yen-Ju Chen, et al. Impacts of Intralipid on Nanodrug Abraxane Therapy and on the Innate Immune System. Sci Rep. 2020 Feb 18;10(1):2838. |